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Diabetes mellitus is associated with a higher risk of target lesion revascularization (TLR) after 
percutaneous coronary intervention. We compared clinical outcomes in patients with and 
without diabetes mellitus, treated with everolimus-eluting stents (EES; Synergy; Boston 
Scientific, Marlborough, MA, USA) or biolimus-eluting stents (BES; BioMatrix NeoFlex; 
Biosensors Interventional Technologies Pte Ltd., Singapore). In total, 2,764 patients were 
randomized to stent implantation with EES (n=1,385, diabetes: n=250) or the BES (n=1,379, 
diabetes: n=262), stratified by sex and diabetes. The primary endpoint, target lesion failure 
(TLF), was a composite of cardiac death, target-lesion myocardial infarction, or TLR at 12 
months. Secondary endpoints included individual components of TLF, all-cause death, and 
stent thrombosis. TLF was 2.1% lower in the EES vs the BES groups in patients with diabetes 
(3.6% vs 5.7%; RR 0.61, 95% confidence interval [CI] 0.27-1.41) and similar in patients 
without diabetes (4.1% vs 4.0%; RR 0.99, 95% CI 0.66-1.51). Among patients with diabetes, 
the point estimates of the individual components of TLF also favored the EES but confidence 
intervals were wide. No interaction between stent type and presence of diabetes was found. 
The current subgroup analysis found that a thin-strut EES as compared to a thicker-strut BES 
had a numerically lower TLF rate among patients with diabetes, but the subgroup analysis 
was underpowered for definite conclusions. 
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Diabetes mellitus is associated with an increased risk of restenosis and major adverse 
cardiovascular events after percutaneous coronary intervention (PCI).
1-3
 Guidelines 
recommend implantation of new-generation drug-eluting stents (DES) in diabetes patients 
undergoing PCI due to higher safety and efficacy compared to early-generation DES and 
bare-metal stents.
4
 The Scandinavian Organization for Randomized Trials with Clinical 
Outcome (SORT OUT) VIII trial compared 2 new-generation DES with biodegradable 
polymers: the thin-strut platinum-chromium everolimus-eluting stent (EES; Synergy) versus 
the stainless-steel biolimus-eluting stent (BES; BioMatrix NeoFlex). At 12-month follow-up, 
EES was non-inferior to BES with respect to target lesion failure (TLF) in routine clinical 
care patients.
5
 In this prespecified substudy, we examined 12-month clinical outcomes in 
patients with and without diabetes treated with EES or BES. 
Methods 
SORT OUT VIII is a randomized, multi-centre, all-comers, two-arm, non-inferiority 
trial comparing EES to BES in treating coronary and graft lesions. Patients were eligible if 
they were ≥18 years old, had chronic stable coronary artery disease or acute coronary 
syndromes, and ≥1 coronary or graft lesion with >50% diameter stenosis. A detailed 
description of study protocol, including inclusion and exclusion criteria, was reported in the 
main publication.
5
 This trial was registered with ClinicalTrials.gov (NCT02093845).  
Block randomization by centre was used to assign patients in a 1:1 ratio to receive the 
EES (Synergy; Boston Scientific, Marlborough, MA, USA) or the BES (BioMatrix NeoFlex; 
Biosensors Interventional Technologies Pte Ltd., Singapore). The allocation sequence was 













to have diabetes if they received glucose-lowering medications or reported dietary treatment 
for diabetes combined with haemoglobin A1c above the diagnostic threshold for diabetes.
3,6-8
 
The primary endpoint, TLF, was a composite of safety (cardiac death and myocardial 
infarction [MI] not clearly attributable to a non-target lesion) and efficacy (clinically indicated 
target lesion revascularization [TLR]) within 12 months. Secondary endpoints were: cardiac 
death; all-cause death; MI; clinically indicated TLR; clinically indicated target vessel 
revascularization (TVR); definite, probable, or possible stent thrombosis; device delivery 
failure; and patient-related composite endpoint defined as a combination of all-cause death, 
any MI, and any clinically indicated revascularization (TVR and non-TVR).   
Distributions of continuous variables in the study groups were compared using 2-
sample t test (or Cochran test in the case of unequal variance) or the Mann-Whitney U test, 
depending on whether data followed a normal distribution. Distributions of categorical 
variables were evaluated using the 𝜒2 test. Follow-up began on the date of the index PCI 
procedure and continued until the date of an endpoint event, death, emigration, or 12 months 
after stent implantation, whichever came first. Cumulative incidence curves were constructed 
based on cumulative incidence of endpoint events, accounting for competing risk of death. 
Rate ratios (RRs) were calculated using BES as reference. All analyses were performed 
following intention-to-treat principles. P-values were 2-sided with a significance threshold of 
<0.05. We used SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) for all statistical 
analyses.  
Results 
A total of 2,764 patients were included in the study. In the BES group, 2 patients were 













Baseline patient characteristics (Table 1) and procedural characteristics (Table 2) were 
well balanced in both diabetes and non-diabetes patients treated with EES versus BES. 
Compared to patients without diabetes, those with diabetes had higher body mass index, were 
more often treated for hypertension and hypercholesterolemia, and more frequently had a 
history of MI, PCI, and coronary artery bypass grafting. Furthermore, diabetes patients had a 
greater burden of comorbidity, and fewer were active smokers. Patients with diabetes were 
more commonly treated with >1 stent and fewer received bivalirudin compared to patients 
without diabetes, the latter reflecting a lower number of STEMI patients in the diabetes 
subgroup.  
The clinical endpoints are presented in Figure 1. The cumulative risk of TLF is 
illustrated in Figure 2. At 12-month follow-up, TLF was 3.6% in the EES group and 5.7% in 
the BES group in patients with diabetes (RR 0.61, 95% confidence interval [CI] 0.27-1.41). In 
patients with diabetes, the RRs of secondary endpoints were in favor of the EES, but CI’s 
were wide and none of the endpoints were statistically significant. Patients without diabetes 
had a similar risk of both TLF (4.1% with EES vs 4.0% with BES; RR 0.99, 95% CI 0.66-
1.51) and the secondary endpoints. No interaction between stent type and presence of diabetes 
was found.  
Discussion 
This SORT OUT VIII substudy provides a 12-month head-to-head comparison of the 
Synergy EES and the BioMatrix NeoFlex BES in patients with and without diabetes. Our trial 
showed no significant differences between stent type neither for patients with diabetes nor for 













compared to the BES group among patients with diabetes and the lack of significance may 
reflect insufficient power in a subgroup analysis.  
SORT OUT VIII is the first trial comparing the EES vs BES.
5
 These stents differ 
concerning strut thickness (74-79 μm vs 112 μm), absorption period of the polymer (~4 
months vs ~6-9 months), stent material (platinum chromium vs stainless steel), and the eluted 
drug. Thinner stent struts have been associated with less thrombogenicity
9
 and superior 
clinical outcomes with reduced risk of restenosis.
10,11
 Accordingly, experimental results have 
demonstrated less acute thrombogenicity of the thin-strut Synergy EES compared to the 
BioMatrix BES.
12
 In the main SORT OUT VIII publication, however, we found non-
inferiority between the 2 DES.
5
  
Diabetes patients may serve as a “stress test” when evaluating the clinical performance 
of stents due to increased risk of restenosis and major adverse cardiovascular events after 
PCI.
1-3
 Thus, our study suggests a potential 39% relative risk reduction of TLF with EES 
compared to BES, although the wide CIs make this point estimate uncertain. Moreover, as 
illustrated in Figure 1, the point estimates favor EES for all endpoints among patients with 
diabetes. Additionally, rate of stent delivery failure was twice as high in the BES treated 
diabetes patients. This is likely associated with BES having thicker struts and thus being more 
difficult to advance in complex lesions.  
As previously demonstrated in other SORT OUT substudies, patients with diabetes 
showed greater differences between first-generation DES and second-generation DES than 
patients without diabetes.
6,7
 Second-generation DES, however, have narrowed the gap 
between different DES, also in patients with diabetes.
8,13,14
 In the SORT OUT III diabetes 
substudy, major adverse cardiac events differed between the Cypher sirolimus-eluting stent 













18.3%) and 5-year follow-up (18.5% vs 28.4%).
6,7
 Major adverse cardiac events occurring 
between 12 to 60 months follow-up, however, did not differ between SES and ZES (15% in 
both groups).
7
 In the SORT OUT IV diabetes substudy, the Xience V EES had a 5.5% lower 
risk of major adverse cardiac events than the Cypher Select+ SES (10.3% vs 15.8%) at 18-
month follow-up.
3
 In SORT OUT VII, 2-year TLF rate was similar in diabetes patients treated 
with 2 new-generation DES (Orsiro SES 9.3% vs Nobori BES 9.4%), both using a 
bioarbsorbable polymer for drug delivery.
8
 Finally, in the BIONICS trial, outcomes were 
similar between patients treated with ridaforolimus-eluting and zotarolimus-eluting stents at 
2-year follow-up, regardless of diabetes status.
13
  Here we found that TLF was numerically 
lower with the Synergy EES compared to the BioMatrix NeoFlex BES in patients with 
diabetes, which is comparable to the BIO-RESORT trial that also reported numerically fewer 
TLF events with the Synergy EES compared to the Resolute Integrity ZES (5.9% vs 8.1%) at 
12-month follow-up in patients with diabetes.
15
  
The present study has limitations. First, this subgroup analysis, as is any subgroup, 
would not have sufficient power in the individual subgroups. A sufficiently powered study 
(alpha 0.05, beta 0.2) in diabetes patients would require approximately 1600 diabetes patients 
per stent group to adequately confirm the observed 2.1% TLF difference. Second, the 
registry-based endpoint design with adjudication by an endpoint committee corresponds to 
outcome assessment in conventional randomized clinical trials, the only exceptions being 
stent thrombosis and TVR/TLR that were classified by 2 dedicated PCI operators.
5
  
In conclusion, the SORT OUT VIII diabetes substudy showed no significant 
differences between the biodegradable-polymer Synergy EES and the biodegradable-polymer 
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Figure 1. One-year clinical outcomes among randomized patients with and without diabetes 
mellitus treated with everolimus-eluting stents (EES) or biolimus-eluting stents (BES). CI = 
confidence interval; MI = myocardial infarction; TLR = target lesion revascularization; TVR 
































target vessel-related myocardial infarction, and target lesion revascularization [TLR]) in 
patients with and without diabetes after implantation with everolimus-eluting (solid line) or 
















Table 1. Baseline characteristics of patients with and without diabetes mellitus 






















Age (years), mean±SD 66.6±11.3 67.1±10.7 0.62 66.3±11.1 66.1±10.6 0.78 0.09 
Men 180 (72.0%) 194 
(74.0%) 
0.60 880 (77.5%) 862 
(77.2%) 
0.84 0.04 
Current smoker 67 (28.4%) 55 (22.0%) 0.10 351 (32.5%) 330 
(31.1%) 
0.51 0.004 




29.8±5.9 30.0±7.8 0.78 27.3±4.4 27.3±4.5 0.96 <0.001 
Hypertension 185 (74.0%) 210 
(80.2%) 
0.25 592 (52.2%) 585 
(52.4%) 
0.11 <0.001 
Hypercholesterolemia 187 (74.8%) 197 
(75.2%) 









coronary intervention  




artery bypass grafting 
40 (16.1%) 31 (12.0%) 0.18 104 (9.2%) 81 (7.3%) 0.11 <0.001 
Clinical presentation   0.09   0.98 <0.001 
   ST-segment elevation 
myocardial infarction 
32 (12.8%) 37 (14.1%)  255 (22.5%) 247 
(22.1%) 
  




96 (38.4%) 75 (28.6%)  370 (32.6%) 370 
(33.1%) 
  
   Stable angina pectoris 106 (42.4%) 136 
(51.9%) 
 472 (41.6%) 460 
(41.2%) 
  
   Other 16 (6.4%) 14 (5.3%)  38 (3.3%) 40 (3.6%)   
Anti-diabetes treatment   0.07     
   Diet-only 13 (5.2%) 21 (8.0%)      
   Non-insulin 
medication 
119 (47.6%) 145 
(55.3%) 
     
   Insulin (±non-insulin  
   medication) 
89 (35.6%) 77 (29.4%)      
   Missing 29 (11.6%) 19 (7.3%)      
Comorbidity Index 
score 
  0.89   0.45 <0.001 
   0 62 (24.8%) 68 (26.0%)  681 (60.0%) 699 
(62.6%) 
  
   1-2 101 (40.4%) 108 
(41.2%) 
 353 (31.1%) 327 
(29.3%) 
  
   ≥3 87 (34.8%) 86 (32.8%)  101 (8.9%) 91 (8.1%)   


















Table 2. Baseline lesion and procedure characteristics of patients with and without diabetes mellitus 




















Number of lesions 322 331  1,403 1,339   
Target lesions per patient   0.70   0.64 0.16 
    1 154 (62.6%) 157 (61.1%)  751 (66.3%) 758 (68.0%)   
    2 61 (24.8%) 69 (26.8%)  248 (21.9%) 233 (20.9%)   
    3 18 (7.3%) 24 (9.3%)  87 (7.7%) 79 (7.1%)   
    >3 13 (5.2%) 7 (2.7%)  46 (11.8%) 44 (4.0%)   
Target lesion coronary 
vessel 
  0.70   0.45 0.10 
    Left main 10 (3.1%) 11 (3.3%)  33 (2.4%) 22 (1.6%)   
    Left ant. descending 120 (37.3%) 137 (41.4%)  598 (42.6%) 575 (42.9%)   
    Left circumflex 78 (24.2%) 72 (21.8%)  289 (20.6%) 303 (22.6%)   
    Right  103 (32.0%) 104 (31.4%)  458 (32.6%) 414 (30.9%)   
    Saphenous vein graft 11 (3.4%) 7 (2.1%)  25 (1.8%) 25 (1.9%)   
Lesion type   0.46   0.97 0.25 
    A 46 (14.3%) 46 (13.9%)  174 (12.4%) 172 (12.8%)   
    B1 85 (26.4%) 106 (32.0%)  425 (30.3%) 398 (29.7%)   
    B2 70 (21.7%) 64 (19.3%)  334 (23.8%) 314 (23.5%)   
    C 121 (37.6%) 115 (34.7%)  470 (33.5%) 455 (34.0%)   
Long-term total 
occlusion lesions 
16 (5.0%) 17 (5.1%) 0.94 63 (4.5%) 74 (5.6%) 0.21 0.96 
Bifurcation lesions 60 (18.7%) 53 (16.0%) 0.37 231 (16.5%) 218 (16.4%) 0.90 0.59 











Reference vessel size, 










Total stent length (mm), 
median: Q1-Q3 
       


















>1 stent used 92 (37.4) 100 (38.9) 0.73 244 (21.5) 230 (20.6) 0.60 0.02 
Maximum pressure 










Direct stenting 33 (10.4%) 37 (11.3%) 0.69 172 (12.3%) 175 (13.1%) 0.53 0.21 
Stent delivery failure 4 (1.2%) 8 (2.4%) 0.26 25 (1.8%) 36 (2.7%) 0.11 0.69 
Length of procedure 
































Use of glycoprotein 
IIb/IIIa inhibitors 
6 (2.4%) 12 (4.6%) 0.18 31 (2.7%) 33 (3.0%) 0.75 0.42 
Use of Bivalirudin 36 (15.9%) 32 (13.1%) 0.31 265 (25.0%) 249 (23.9%) 0.86 <0.001 
Values are presented as number of patients (percentage) unless otherwise stated.   
Q1 = 1
st
 quartile; Q3 = 3
rd
 quartile. 
 
 
 
